Company intelligence / Profile preview

272BIO

Reading, Berkshire, United Kingdom272bio.com ↗

Ownership: Private
Employees: ~22
Development stage: Preclinical

Overview

272BIO is developing a pipeline of VHH-based therapeutic and prophylactic drugs for complex veterinary diseases. Their approach leverages the flexibility and modularity of VHH antibodies to create affordable, second-generation treatments for companion animals and livestock. No published clinical results yet.

Therapeutic areas: OncologyImmunologyDermatologyRheumatologyNephrology
Modalities: VHH antibodies (single-domain antibodies, also known as nanobodies)Biotherapeutics
Industry: Veterinary

Beyond the preview

Go deeper on 272BIO.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 272BIO.

Explore the full profile